This is really positive too:
An exploratory subgroup analysis was conducted in patients with a prior anti-VEGF-A treatment history
of only receiving previous Eylea to assess the effects of OPT-302 combination therapy following the most
optimal first-line standard of care used to achieve maximal VEGF-A inhibition. In this subgroup, the mean
change in BCVA at week 12 compared to baseline was 8.6 letters for OPT-302 + Eylea and 5.0 letters in
patients who continued on Eylea monotherapy. The proportion of patients in the subgroup gaining ≥10
and ≥15 letters from baseline to week 12 was 50% and 16.7% in the OPT-302 combination group
respectively and 0% for both parameters in the Eylea control. The percentage of patients losing 1 or
more letters from baseline to week 12 was 8.3% in the OPT-302 + Eylea group, and 12.5% for the Eylea
control.
- Forums
- ASX - By Stock
- Ann: Opthea Reports Positive Ph2a Trial Results of OPT-302 in DME
This is really positive too: An exploratory subgroup analysis...
-
- There are more pages in this discussion • 119 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add OPT (ASX) to my watchlist
|
|||||
Last
56.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $695.5M |
Open | High | Low | Value | Volume |
57.5¢ | 57.5¢ | 55.0¢ | $706.9K | 1.260M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
3 | 79437 | 55.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
57.0¢ | 174437 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
2 | 29437 | 0.555 |
2 | 47582 | 0.550 |
1 | 29437 | 0.545 |
2 | 7254 | 0.540 |
4 | 21773 | 0.530 |
Price($) | Vol. | No. |
---|---|---|
0.570 | 174437 | 2 |
0.575 | 59437 | 2 |
0.580 | 38513 | 7 |
0.590 | 15500 | 1 |
0.595 | 103600 | 2 |
Last trade - 16.10pm 03/09/2024 (20 minute delay) ? |
Featured News
OPT (ASX) Chart |